Professor Michael Chan received his PhD degree in Medical Science from the Chinese University of Hong Kong, and did his post-doctoral fellowship in influenza virus and infectious diseases at the University of Hong Kong.
Professor Chan’s main research interests are virus-host interactions and pathogenesis of influenza virus and coronavirus (SARS-CoV-2, SARS-CoV and MERS-CoV) in ex vivo cultures and in vitro cells of the human respiratory tract. His current work encompasses multiple aspects of influenza virus and coronavirus, including human respiratory organoids development, risk assessment, lung injury mechanism upon infection, as well as therapeutic options for severe infection.
Professor Chan has been a Lead Scientist at the InnoHK Centre for Immunology & Infection since 2020 and is also the Founder and CEO of the spin-off company C2iTech, where he has developed cutting-edge service platforms for academia and industry specialising in infectious diseases, as well as innovative solutions for organoid development.